Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Actinogen Medical ( (AU:ACW) ) is now available.
Actinogen Medical has completed a $16.8 million capital raise, including $4.8 million from a share purchase plan offered to existing shareholders on the same terms as a prior placement. The new funding lifts its pro forma 31 December 2025 cash balance to $29.5 million, significantly strengthening its financial position.
The company says the expanded cash runway will fund key 2026 initiatives, including starting an open-label extension study and completing non-clinical work, while supporting completion of its pivotal XanaMIA phase 2b/3 Alzheimer’s disease trial by November 2026. Management highlighted strong support from both institutional and retail investors, underlining market confidence in Xanamem’s prospects in the Alzheimer’s treatment landscape.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company developing Xanamem, a novel therapy targeting neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Its lead focus is Alzheimer’s disease, alongside prior work in depression and potential future studies in Fragile X syndrome and other brain disorders, aiming to address significant unmet medical need.
Average Trading Volume: 5,255,284
Technical Sentiment Signal: Hold
Current Market Cap: A$148.9M
See more data about ACW stock on TipRanks’ Stock Analysis page.